Compare FTAI Aviation Ltd (FTAI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Johnson & Johnson — how do they compare? FTAI Aviation Ltd trades at $169.8 (market cap $17.57B), while Johnson & Johnson trades at $260.78 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 35.2× FTAI Aviation Ltd's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 23 Days and Johnson & Johnson for 129 Days on average.
| FTAI | JNJ | |
|---|---|---|
Market Cap | $17.57B | $618.09B |
Volume | 1,905,014 | 6,050,983 |
Sector | Industrials | Health |
52-Week High | $310.04 | $278.43 |
52-Week Low | $152.80 | $186.00 |
Typical Hold Time | 23 Days | 129 Days |
Enterprise Value | $20.69B | $646.37B |
Dividend Yield | 1.17% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $169.47, down 3.07% today, with a bearish technical signal from moving averages. The company reported strong 2025 revenue of $2.51B and net income of $501M, though recent quarters have missed EPS expectations. Recent developments include a $500M share buyback program and a strategic acquisition of 27 Boeing aircraft, signaling growth focus. Analyst consensus remains unanimously bullish with a $321.25 price target, highlighting institutional confidence despite near-term earnings volatility.
The outlook for FTAI is positive based on robust analyst support and strategic expansions, but risks include consecutive EPS misses and a high P/E ratio of 37.35. Investors face volatility from operational cash flow challenges and competitive pressures in the aviation sector, though the buyback and new partnerships provide catalysts for recovery.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
